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LETTERS
increased macrolide use in the United 
States during 1995–1999 coincided 
with a doubling of the proportion of 
macrolide-resistant pneumococci (4), 
and further increases in macrolide 
use since 1999 (3) have contributed 
to the increase in macrolide-resistant 
pneumococci.
Decreased macrolide use has led 
to a decrease in macrolide-resistant 
pneumococci. A yearly seasonal re-
duction in antimicrobial drug pre-
scribing in Israel was associated with 
a decrease in the proportion of antimi-
crobial drug–resistant pneumococci 
that caused acute otitis media (5). With 
the introduction of expanded-valent 
pneumococcal conjugate vaccines, 
there is promise that drug-resistant 
pneumococcal disease can be reduced. 
Nevertheless, judicious use of anti-
microbial drugs and a decrease in un-
necessary prescriptions, as promoted 
by the Get Smart: Know When Anti-
biotics Work (www.cdc.gov/getsmart) 
campaign, are essential to limiting 
selection and spread of antimicrobial 
drug resistance.
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Rapid Antigen 
Test for Pandemic 
(H1N1) 2009 Virus
To the Editor: Drexler et al. re-
cently compared the sensitivity of the 
BinaxNOW Inﬂ  uenza A & B Rapid 
Test (BinaxNOW; Inverness Medi-
cal, Cologne, Germany) with that of 
a real-time reverse transcription–PCR 
(RT-PCR) assay speciﬁ  c for inﬂ  uenza 
A pandemic (H1N1) 2009 virus (1). 
Of 1,838 clinical specimens tested, 
221 were conﬁ   rmed as positive for 
pandemic (H1N1) 2009 by RT-PCR. 
When 144 of these 221 specimens 
were evaluated by using the Binax-
NOW, results were positive for only 
16 (11%).
At onset of the pandemic, we 
evaluated the ﬁ  rst 135 nasopharyngeal 
aspirates submitted to the Regional 
Laboratory of Public Health Haar-
lem, the Netherlands. We compared 
the performance of the BinaxNOW 
for diagnosing inﬂ  uenza  A  (H1N1) 
virus by using molecular detection of 
inﬂ  uenza virus as the reference stan-
dard. Samples were analyzed with a 
general inﬂ   uenza A assay targeting 
the matrix gene (the RespiFinder as-
say) (PathoFinder B.V., Maastricht, 
the Netherlands [2]) and a pandemic 
(H1N1) 2009–speciﬁ   c RT-PCR as-
say targeting the neuraminidase gene 
(3). We tested 135 patient samples (76 
from male patients); mean age of pa-
tients was 32 years (range 0–81 years). 
Samples from 38 (28%) patients had 
positive results in both RT-PCRs, and 
samples from 97 (72%) patients had 
negative results in the matrix gene RT-
PCR and neuraminidase RT-PCR as-
says. Sensitivity and speciﬁ  city were 
estimated to be 47% (18/38, 95% con-
ﬁ  dence interval [CI] 32%–62%) and 
95% (92/97, 95% CI 88%–98%), re-
spectively, for the BinaxNOW antigen 
test. Patients’ ages did not signiﬁ  cantly 
differ between rapid test–positive and 
–negative results.
Our results largely agree with 
those of Vasoo et al. (4) and the Cen-
ters for Disease Control and Preven-
tion (5). Those studies determined that 
the sensitivity of the BinaxNOW com-
pared with nucleic acid ampliﬁ  cation 
tests is ≈40%. The lower sensitivity 
observed by Drexler et al. (1) might 
be because of differences in study type 
(retrospective evaluation compared 
with a prospective cohort in our study), 
sample size, technical factors (with re-
gard to specimen collection, specimen 
transport, and specimen storage), dif-
ferences in the test kit, and differences 
between individual patients (multiple 
categories of age and stages of illness, 
differences in virus shedding).
Many clinicians are not aware of 
the performance of speciﬁ  c  test  de-
vices and rely on test results to make 
clinical decisions. Because negative 
results cannot rule out inﬂ  uenza, this 
test is of little use in a clinical setting 
without appreciation of the limitations 
of the test. However, because the Bi-
naxNOW has reasonable speciﬁ  city, 
it might prove useful in clinical or 
epidemiologic situations in which test 
sensitivity is not critical, e.g., in facil-
ity outbreaks in which multiple speci-
mens are collected to rapidly identify 
the causative organism.
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In Response: We read with in-
terest the report by Diederen et al. 
(1) showing a 47% sensitivity of the 
BinaxNOW (Inverness Medical, Co-
logne, Germany) antigen-based rapid 
inﬂ   uenza diagnostic test (RIDT) for 
the clinical detection of pandemic 
(H1N1) 2009 virus. We agree that 
RIDTs may be of little beneﬁ  t in situ-
ations where a timely diagnosis by re-
verse transcription–PCR (RT-PCR) or 
optimized direct ﬂ  uorescent antibody 
tests can be achieved.
Our recent study yielded even 
lower sensitivity for RIDT: 11.1% (2). 
RIDT sensitivity is greatly inﬂ  uenced 
by differences in the level of virus 
shedding between children and adults, 
making studies difﬁ   cult to compare 
(3). In general, age proﬁ  les and virus 
concentrations should be provided 
and considered when comparing co-
horts examined by any virus detec-
tion method. Moreover, quality and 
origin of specimens can inﬂ  uence the 
sensitivity of RT-PCR– and antigen-
based tests. One important example is 
the use of ﬂ  ocked swabs for collect-
ing respiratory samples. Under opti-
mal conditions, for instance, a direct 
ﬂ  uorescent antibody  test was recently 
shown to yield high diagnostic sensi-
tivity comparable with that of RT-PCR 
for pandemic (H1N1) 2009 virus (4). 
Another critical factor, especially for 
RIDT, may be the compatibility of test 
monoclonal antibodies with the novel 
virus. Lower sensitivities of such tests 
for pandemic (H1N1) 2009 virus in 
comparison with seasonal inﬂ  uenza 
viruses have been reported (3,5). Ad-
aptation of RIDT antibody selection 
to pandemic (H1N1) 2009 virus may 
thus be necessary. Finally, we would 
like to emphasize the medical risks 
associated with use of RIDTs by un-
trained operators, e.g., lesions from in-
adequate sampling and false interpre-
tation of test results. Such use may be 
speciﬁ  cally promoted by ready avail-
ability of such tests on the Internet or 
at pharmacies.
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Erratum—Vol. 16, No. 2
The link to the article Hendra Virus Outbreak with Novel Clinical Features, Australia (H. Field et al.) was pub-
lished incorrectly in Vol. 16, No. 4. The correct link is www.cdc.gov/eid/content/16/2/338.htm.